Introduction: Synthetic mid-urethral slings (MUSs) are the gold standard treatment for female stress urinary incontinence (SUI). Recently, there have been reports of serious adverse events with synthetic tapes such as urethral erosion, vaginal erosion, and mesh infection. Tension-free vaginal flap (TVF) operation has been proven to be successful as a natural alternative to synthetic slings. We propose our novel technique, the transobturator tension-free vaginal flap (TO-TVF), utilizing native vaginal tissue and being suspended via transobturator route. Methods: This prospective study was conducted on 72 female patients with SUI, presenting at Alexandria University Hospital. Patients were randomized into 2 groups, group 1: 37 patients subjected to TO-TVF and group 2: 35 patients to conventional transobturator tape (TOT). In TO-TVF, a rectangular vaginal wall flap is created. A polypropylene monofilament mesh is sutured to each edge of the vaginal flap. This is inserted like conventional outside-in TOT. Patients were subjected to PGI and UDI-6 questionnaires and urodynamic study before and 6 months postoperatively. Results: Both groups showed comparable and significant improvements in questionnaires. Mean operative time for TO-TVF and conventional TOT was 26.31 ± 5.2 min and 21.8 ± 3.1 min, respectively. Cure rate was 89% in group 1 and 91.4% in group 2, which was not statistically significant. No significant intraoperative complications were encountered. We had no cases of vaginal or urethral erosion in both groups. Conclusions: TO-TVF is a cost-effective, feasible, safe, and effective surgical alternative to synthetic MUS. Synthetic mesh tissue anchoring properties are maintained for better adjustment of tension. However, long-term follow-up on a large cohort of patients is still needed.

Keywords:
Stress urinary incontinence, Native vaginal tissue, Vaginal flap, Transobturator slings
1.
D’Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433–77.
https://doi.org/10.1002/nau.23897
2.
Sinha S, Agarwal M, Vasudeva P, Khattar N, Madduri VKS, Yande S, et al. The urological society of India guidelines for the evaluation and management of nonneurogenic urinary incontinence in adults (executive summary). Indian J Urol. 2019;35(3):185–8.
https://doi.org/10.4103/iju.IJU_125_19
3.
Milson I, Altman D, Lapitan M, Nelson R, Sillén U, Thom D. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI). Paris: 5th International Consultation on Incontinence (ICUD-EAU); 2013. p. 15–107.
4.
Ulmsten U, Petros P. Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence. Scand J Urol Nephrol. 1995;29(1):75–82.
https://doi.org/10.3109/00365599509180543
5.
Delorme E. Transobturator urethral suspension: mini-invasive procedure in the treatment of stress urinary incontinence in women. Prog Urol. 2001;11(6):1306–13.
6.
Gomes CM, Carvalho FL, Bellucci CHS, Hemerly TS, Baracat F, de Bessa J, et al. Update on complications of synthetic suburethral slings. Int Braz J Urol. 2017;43(5):822–34.
https://doi.org/10.1590/S1677-5538.IBJU.2016.0250
7.
Shah HN, Badlani GH. Mesh complications in female pelvic floor reconstructive surgery and their management: a systematic review. Indian J Urol. 2012;28(2):129–53.
https://doi.org/10.4103/0970-1591.98453
8.
Food and Drug Adminstration (FDA). FDA safety communication: update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. Maryland: FDA; 2011.
9.
NHS improvement and NHS England. Vaginal Mesh: high vigilance restriction period: immediate action required; all cases should be postponed if it is clinically safe to do so. England: NHS; 2018.
10.
Linder BJ, Elliott DS. Autologous transobturator urethral sling placement for female stress urinary incontinence. J Urol. 2015;193(3):991–6.
https://doi.org/10.1016/j.juro.2014.08.125
11.
Fayed AS, El-Salmy S, Shoukry M, Koraitam A, Hassouna M. Tension-free vaginal flap (TVF) for the treatment of stress urinary incontinence in females. Int Cont Soc. 2002;302:118–21.
12.
Shoukry M, Elmissiry M, Hassouna M, Abdelmoteleb H. Outcome of rolled fortified vaginal flap operation on female patients with intrinsic sphincteric deficiency: 2-year follow-up. Int Urogynecol J. 2019;30(3):393–9.
https://doi.org/10.1007/s00192-018-3621-7
13.
Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;2017(7).
https://doi.org/10.1002/14651858.cd006375.pub4
14.
Liapis A, Bakas P, Creatsas G. Burch colposuspension and tension-free vaginal tape in the management of stress urinary incontinence in women. Eur Urol. 2002;41(4):469–73.
https://doi.org/10.1016/s0302-2838(02)00033-7
15.
Richter HE, Albo ME, Zyczynski HM, Kenton K, Norton PA, Sirls LT, et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med. 2010;362(22):2066–76.
https://doi.org/10.1056/NEJMoa0912658
16.
ElSheemy MS, Elsergany R, ElShenoufy A. Low-cost transobturator vaginal tape inside-out procedure for the treatment of female stress urinary incontinence using ordinary polypropylene mesh. Int Urogynecol J. 2015;26(4):577–84.
https://doi.org/10.1007/s00192-014-2552-1
17.
Mangir N, Roman S, Chapple CR, MacNeil S. Complications related to use of mesh implants in surgical treatment of stress urinary incontinence and pelvic organ prolapse: infection or inflammation?World J Urol. 2020;38(1):73–80.
https://doi.org/10.1007/s00345-019-02679-w
18.
Ghoniem GM, Rizk DEE. Renaissance of the autologous pubovaginal sling. Int Urogynecol J. 2018;29(2):177–8.
https://doi.org/10.1007/s00192-017-3521-2
19.
McGuire EJ, Lytton B. Pubovaginal sling procedure for stress incontinence. J Urol. 1978;119(1):82–4.
https://doi.org/10.1016/s0022-5347(17)57390-5
20.
Vasudeva P, Tyagi V, Kumar N, Yadav S, Prasad V, Iyer SG. Mesh free” autologous transobturator mid urethral sling placement for predominant stress urinary incontinence: a pilot study. Neurourol Urodyn. 2021;40(2):659–65.
https://doi.org/10.1002/nau.24599
21.
Ferrari A, Frigerio L. The triangular vaginal patch sling for stress urinary incontinence and hypermobile urethra. Am J Obstet Gynecol. 1997;177(6):1426–31.
https://doi.org/10.1016/s0002-9378(97)70086-3
22.
Illiano E, Trama F, Marchesi A, Fabi C, Brancorsini S, Costantini E. Could the vaginal wall sling still have a role after FDA’s warning? the functional outcomes at 20 years. Ther Adv Urol. 2022 Mar 7;14:17562872221084391.
https://doi.org/10.1177/17562872221084391
23.
Shoukry M, Hassouna ME, AbdEl-Kerim A, El-Salmy S. Rolled vaginal wall flap for the treatment of stress urinary incontinence. Afr J Urol. 2011;17:1–5.
https://doi.org/10.1007/s12301-011-0001-7
24.
Phillips TH, Zeidman EJ, Thompson IM. The fate of buried vaginal epithelium. J Urol. 1992;148(6):1941–3.
https://doi.org/10.1016/s0022-5347(17)37089-1
25.
Altaweel W, Seyam R, Mokhtar A, Kumar P, Hanash K. Arabic validation of the short form of urogenital distress inventory (UDI-6) questionnaire. Neurourol Urodyn. 2009;28(4):330–4.
https://doi.org/10.1002/nau.20640
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.